Alk-Abello ASCHIX:ALKBC 92 PS Ratio is 8.63 as of Jul. 01, 2026, which is 50% above its 10-year median of 5.75. GuruFocus rates CHIX:ALKBC with a GF Score™ of 92/100 and a GF Value™ of kr207.11 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 934 Biotechnology companies, Alk-Abello AS ranks better than 53.21% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Alk-Abello AS's share price is kr256.30.
Alk-Abello AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr29.69. Hence, Alk-Abello AS's PS Ratio for today is 8.63.
Warning Sign:
Alk-Abello AS stock PS Ratio (=8.45) is close to 3-year high of 9.11.
The historical rank and industry rank for Alk-Abello AS's PS Ratio or its related term are showing as below:
CHIX:ALKBc'
s PS Ratio Range Over the Past 10 Years
Min: 2.39 Med: 5.75 Max: 9.73
Current: 8.45
During the past 13 years, Alk-Abello AS's highest PS Ratio was 9.73. The lowest was 2.39. And the median was 5.75.
CHIX:ALKBc's PS Ratio is ranked better than 53.21% of 934
companies
in the Biotechnology industry
Industry Median: 9.515
vs CHIX:ALKBc: 8.45
During the past 12 months, the average Revenue per Share Growth Rate of Alk-Abello AS was 13.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 11.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 12.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.70% per year.
During the past 13 years, Alk-Abello AS's highest 3-Year average Revenue per Share Growth Rate was 13.80% per year. The lowest was -0.50% per year. And the median was 9.65% per year.
Back to Basics: PS Ratio
Alk-Abello AS (CHIX:ALKBc) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Alk-Abello AS PS Ratio Related Terms
Alk-Abello AS PS Ratio Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALKBC vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Alk-Abello AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's PS Ratio distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Alk-Abello AS's Share Price of today is kr256.30. Alk-Abello AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr29.69.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Alk-Abello AS (CHIX:ALKBC) has a PS Ratio of 8.63 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Alk-Abello AS and its competitors. This is 50% above median its historical median of 5.75. Over the past decade, Alk-Abello AS's PS Ratio has ranged from 2.39 to 9.73. According to the industry distribution chart, Alk-Abello AS ranks #437 out of 934 companies in the Biotechnology industry, placing it in the top 46.8%.
Is Alk-Abello AS's PS Ratio too high?
Alk-Abello AS's current PS Ratio of 8.63 is 50% above median its 10-year median of 5.75. Over the past 10 years, this metric has ranged from a low of 2.39 to a high of 9.73. The Biotechnology industry median PS Ratio is 9.52. Alk-Abello AS's value of 8.63 is 9.3% below this industry median. Based on the distribution chart, Alk-Abello AS ranks #437 out of 934 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alk-Abello AS has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #437 out of 934 companies for PS Ratio. This puts Alk-Abello AS in the upper half of its industry. The industry median PS Ratio is 9.52. Alk-Abello AS's value of 8.63 is 9.3% below this benchmark. Historically, Alk-Abello AS's own PS Ratio has ranged from 2.39 to 9.73 over the past decade. While the company's 10-year median is 5.75 vs. the industry median of 9.52, Alk-Abello AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current PS Ratio of 8.63 is 9.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current PS Ratio is 8.63, which is 50% above median its own 10-year median of 5.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr207.11, compared to a current price of kr256.30 — trading 23.8% above its estimated fair value. The current PS Ratio is 8.63, which is 50% above median its 10-year median of 5.75 and 9.3% below the Biotechnology industry median of 9.52. Alk-Abello AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current PS Ratio is 8.63 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of kr256.30 is trading 23.8% above its estimated GF Value™ of kr207.11.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for CHIX:ALKBC:
PS Ratio: 8.63 (50% above median its 10-year median of 5.75)
GF Value™: kr207.11 vs. price of kr256.30 (23.8% above fair value)
Industry Position: 9.3% below the Biotechnology median (#437 of 934)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
92GF Score
Get the complete analysis for CHIX:ALKBC
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
